Ultragenyx Pharma (RARE) Tops Q3 EPS by 33c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Ultragenyx Pharma (RARE) Tops Q3 EPS by 33c

Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update

November 2, 2021 4:05 PM EDT

Third quarter 2021 total revenue of $81.6 million including Crysvita1 revenue to Ultragenyx of $50.3 million

2021 Crysvita revenue in Ultragenyx territories1 now expected towards the upper end of the$180 million to $190 million range previously provided

NOVATO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the third quarter 2021.

In the third quarter we executed on key... More